WillItSurvive
Medical technology and health companies · China

Yidu Tech

yiducloud.com ↗

Chinese healthcare data and AI company that mines hospital records for regulators and drugmakers.

Losing its protection
Assessed 26 July 2026 · Evidence as of 26 July 2026
The structural protection is eroding.
On the recordSince 26 July 2026 · Checkable from November 2026 · Every call on the record Checkpoint: H1 FY2027 interim results, testing whether FY2026 profit repeats or was a one-off cost cut
The call

Yidu just turned its first annual profit on thin margins while Neusoft and iFlytek Healthcare chase the same hospitals and data.

Yidu Tech collects and analyzes medical records from hospitals across China. It has a real advantage because the Chinese government has given it special approval to handle sensitive health data, and 133 hospitals already trust it with their records, which makes it hard for new competitors to enter. However, a rival called Neusoft already claims to lead in similar work, and Yidu only makes modest profits (36 cents per dollar of sales) after losing money for five years. The company's real test comes in late 2026 when investors will see if its new profitability is real or a one-time bounce, and whether it can grow its business beyond lumpy government contracts.

Why
01
AI pressure: iFlytek Healthcare's medical AI tools. iFlytek Healthcare builds AI for the same hospitals and health data, but no contract losses from Yidu are documented yet. Could AI do the core job? Only partly.
02
Bigger players: Neusoft. Neusoft already has hospital ties and an authorized data pathway live in China, competing directly with Yidu for the same accounts. Could a giant copy it? Probably.
03
What protects it. Nine billion authorized medical records plus direct ties to 133 hospitals and 54 regulators, access new entrants cannot easily copy.
What would change this call
Yidu's H1 FY2027 interim results, expected around November 2026. Shows whether FY2026 profit and 14.6% growth continue or were a one-off cost cut.
Neusoft or iFlytek Healthcare publicly winning a named provincial hospital or regulator contract (e.g. Hainan, Beijing, Henan). Would show Yidu losing ground to a named competitor in its core market.
Tencent or Alibaba Health launching a competing authorized medical-data platform and bidding on provincial RFPs. Would show a large tech player entering Yidu's regulated-data niche.
Key numbers
  • FY2026 revenue RMB 819.3M, up 14.6% YoY (2026-03-31)
  • First full-year net profit: RMB 78.8M (2026-03-31)
  • 133 hospitals and 54 regulators served (2026-03-31)
Named risks
  • First-ever FY2026 profit may be a one-off cost-cutting result rather than sustained improvement. Severity: high
  • Crowded competitive field with Neusoft, iFlytek Healthcare, and Medlive contesting same hospitals and regulators. Severity: medium
  • Prior five years of losses and flat-to-declining revenue base before FY2026 rebound. Severity: medium
  • Thin gross margins (~36%) reflect services-grade rather than software-grade economics. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
NeusoftcontestingClaims #1 in clinical data intelligence solutions per vendor-cited IDC report, Oct 2025
iFlytek HealthcarecontestingBenchmarked against Yidu Tech on profitability and valuation multiples, April 2026
Medlive TechnologycontestingComparable HKEX-listed healthcare-data peer, ~HK$5.6bn market cap, July 2026
Tencent/Alibaba Healthgaining onInternet giants expanding healthcare AI ambitions that could compete with Yidu's data platform, 2026
Questions people ask
Is Yidu Tech profitable in 2026?
Yes. For FY2026 (year ended 31 March 2026), Yidu Tech reported its first-ever full-year net profit of RMB 78.8 million (RMB 72.7 million attributable to owners), reversing a loss the prior year, per its HKEX filing dated 30 June 2026.
Who owns Yidu Tech?
Yidu Tech Inc. (HKEX: 2158, ADR: YDUTY) is a standalone public company, not a subsidiary. It IPO'd on the Hong Kong Stock Exchange on 15 January 2021, with Tencent as a cornerstone investor alongside OrbiMed and CPPIB.
Is Yidu Tech's biggest competitor Neusoft?
Neusoft claims to be #1 in China's clinical data intelligence solutions market per an IDC report it cited on 28 October 2025 (vendor-claimed). Yidu Tech also competes with iFlytek Healthcare and Medlive Technology in the same healthcare-AI-data space.
Could AI replace Yidu Tech?
Unlikely soon. Yidu Tech is itself an AI vendor whose moat is nearly 9 billion authorized medical records and ties to 133 hospitals and 54 regulators (as of 31 March 2026), a compliance and data-access position generic LLMs cannot replicate in China's regulated system.
What is Yidu Tech's revenue growth rate?
Yidu Tech's FY2026 revenue reached RMB 819.3 million, up 14.6% year-on-year from RMB 715.0 million in FY2025, according to its annual results announcement filed with HKEX on 30 June 2026.
Is Yidu Tech stock a good investment?
Yidu Tech's stock fell about 25.7% over the trailing year to July 2026, though it outperformed the broader Hong Kong healthcare-services index, which dropped roughly 42.4% in the same period, per simplywall.st data dated 19 July 2026.
Timeline
  • 2026-07-24AGM set for 28 Aug 2026 to approve FY2026 accounts, HK$0.04/share dividend, board mandates
  • 2026-07-02Yidu Tech announces first-ever full-year profit, RMB 78.8M net profit for FY2026
  • 2026-06-30HKEX Annual Results Announcement for FY2026 filed
  • 2026-04-24Analyst commentary flags uncertainty over sustained profitability
  • 2026-03-10Yidu Evidence, an evidence-based clinical AI assistant, launched
  • 2025-11-27H1 FY2026 interim results announcement filed with HKEX
  • 2025-10-28Neusoft claims #1 rank in clinical data intelligence solutions (vendor-authored IDC report)
  • 2021-01-15Yidu Tech IPOs on HKEX, Tencent-backed, shares surge on debut
Revision history
26 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources